About this webinar:
China is a key player in the oncology market, with significant investment, commanding $30 billion in oncology licensing deals, tripling US output in 2024. In the first quarter of 2025 alone, Chinese companies accounted for 32% of global biotech licensing deal value.
This webinar addresses:
- Cross-border collaboration and geopolitical forces reshaping biotech innovation between China and the West
- Innovation transfer from discovery to development and commercialization
- Deal structures, capital flows, and evolving models of licensing and investment across U.S., European, and Chinese biopharma
About IO360º, the webinar’s associated conference:
IO360˚ is an annual conference that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. Visit www.IO360summit.com for more information.
About BioVerse:
BioVerse, launched by InScienceWeTrust Community in 2022, is a leading biotech webinar series co-produced with SAPA-GP, BioSpark, and eight other collaborators. Highlighting Asian biotech's global impact, BioVerse has produced 18 episodes, averaging 12,000 live attendees per episode, and 220,000+ accumulated unique views. Access past episodes on YouTube and join our mailing list for updates on future episodes.
Moderators
Speakers
